Nishit Shah Email

Senior Research Associate . Akston Biosciences Corporation

Current Roles

Employees:
89
Revenue:
$13.8M
About
Akston Biosciences Corporation is a leader in the field of insulin engineering.  The company was founded in 2011 by the former SmartCells, Inc. team who developed the world’s first clinical glucose-responsive insulin (acquired by Merck & Co. in 2010).  Combining its core expertise with modern biotechnology manufacturing techniques, Akston is developing new classes of biologic therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long acting insulin therapy, and oncology to dramatically improve both human and animal health.  The company has raised over $18 million in equity financing from the management team and private investors, as well as $10 million from the NIH and the Helmsley Charitable Trust.
Akston Biosciences Corporation Address
100 Cummings Center
Beverly, MA
United States
Akston Biosciences Corporation Email

Past Companies

Akston Biosciences CorporationSenior Engineer I
Akston Biosciences CorporationScientist II
Akston Biosciences CorporationScientist I